Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence

Howard Chung,1,2 Peter HR Green,1,3 Timothy C Wang,1 Xiao-Fei Kong1,3 1Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA; 2Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/Queens (Queens Hospi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chung H, Green PH, Wang TC, Kong XF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	down syndrome interferon receptors jak-stat celiac disease t cells gene dosage effect Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/8e4b711846f244ca8c2982cd423519d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e4b711846f244ca8c2982cd423519d0
record_format	dspace
spelling	oai:doaj.org-article:8e4b711846f244ca8c2982cd423519d02021-12-02T16:59:45ZInterferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence1178-7031https://doaj.org/article/8e4b711846f244ca8c2982cd423519d02021-10-01T00:00:00Zhttps://www.dovepress.com/interferon-driven-immune-dysregulation-in-down-syndrome-a-review-of-th-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Howard Chung,1,2 Peter HR Green,1,3 Timothy C Wang,1 Xiao-Fei Kong1,3 1Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA; 2Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/Queens (Queens Hospital Center), Jamaica, NY, 11432, USA; 3Celiac Disease Center, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USACorrespondence: Xiao-Fei KongDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, 622 West 168th ST, PH7W Suite 318, New York, NY, 10032, USAEmail xk2137@cumc.columbia.eduAbstract: Down syndrome (DS) is a unique genetic disease caused by the presence of an extra copy of chromosome 21, which carries four of the six interferon receptor (IFN-R) genes on its long arm. Recent studies reporting higher levels of interferon-stimulated gene (ISG) expression in primary immune cells studied ex vivo have suggested that the additional copies of the IFN-R genes in DS result in mild interferonopathy. In this review, we analyze the potential clinical and immunological impacts of this interferonopathy in DS. We performed a literature review to explore the epidemiology and risks of celiac disease, type 1 diabetes, thyroid dysfunction, mucocutaneous manifestations, infectious diseases (including COVID-19), and Alzheimer’s disease in individuals with DS relative to the general population with or without iatrogenic exposure to interferons. We analyzed immunophenotyping data and the current experimental evidence concerning IFN-R expression, constitutive JAK-STAT activation, and ISG overexpression in DS. Despite the lack of direct evidence that implicating this mild interferonopathy directly in illnesses in individuals with DS, we highlight the challenges ahead and directions that could be taken to determine more clearly the biological impact of interferonopathy on various immune-related conditions in DS.Keywords: down syndrome, interferon receptors, JAK-STAT, celiac disease, T cells, gene dosage effectChung HGreen PHWang TCKong XFDove Medical Pressarticledown syndromeinterferon receptorsjak-statceliac diseaset cellsgene dosage effectPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 5187-5200 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	down syndrome interferon receptors jak-stat celiac disease t cells gene dosage effect Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	down syndrome interferon receptors jak-stat celiac disease t cells gene dosage effect Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Chung H Green PH Wang TC Kong XF Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
description	Howard Chung,1,2 Peter HR Green,1,3 Timothy C Wang,1 Xiao-Fei Kong1,3 1Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA; 2Department of Internal Medicine, Icahn School of Medicine at Mount Sinai/Queens (Queens Hospital Center), Jamaica, NY, 11432, USA; 3Celiac Disease Center, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USACorrespondence: Xiao-Fei KongDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University Irving Medical Center, 622 West 168th ST, PH7W Suite 318, New York, NY, 10032, USAEmail xk2137@cumc.columbia.eduAbstract: Down syndrome (DS) is a unique genetic disease caused by the presence of an extra copy of chromosome 21, which carries four of the six interferon receptor (IFN-R) genes on its long arm. Recent studies reporting higher levels of interferon-stimulated gene (ISG) expression in primary immune cells studied ex vivo have suggested that the additional copies of the IFN-R genes in DS result in mild interferonopathy. In this review, we analyze the potential clinical and immunological impacts of this interferonopathy in DS. We performed a literature review to explore the epidemiology and risks of celiac disease, type 1 diabetes, thyroid dysfunction, mucocutaneous manifestations, infectious diseases (including COVID-19), and Alzheimer’s disease in individuals with DS relative to the general population with or without iatrogenic exposure to interferons. We analyzed immunophenotyping data and the current experimental evidence concerning IFN-R expression, constitutive JAK-STAT activation, and ISG overexpression in DS. Despite the lack of direct evidence that implicating this mild interferonopathy directly in illnesses in individuals with DS, we highlight the challenges ahead and directions that could be taken to determine more clearly the biological impact of interferonopathy on various immune-related conditions in DS.Keywords: down syndrome, interferon receptors, JAK-STAT, celiac disease, T cells, gene dosage effect
format	article
author	Chung H Green PH Wang TC Kong XF
author_facet	Chung H Green PH Wang TC Kong XF
author_sort	Chung H
title	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
title_short	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
title_full	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
title_fullStr	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
title_full_unstemmed	Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence
title_sort	interferon-driven immune dysregulation in down syndrome: a review of the evidence
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/8e4b711846f244ca8c2982cd423519d0
work_keys_str_mv	AT chungh interferondrivenimmunedysregulationindownsyndromeareviewoftheevidence AT greenph interferondrivenimmunedysregulationindownsyndromeareviewoftheevidence AT wangtc interferondrivenimmunedysregulationindownsyndromeareviewoftheevidence AT kongxf interferondrivenimmunedysregulationindownsyndromeareviewoftheevidence
_version_	1718382280173420544

Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence

Ejemplares similares